ONCOLYTICS BIOTECH INC

NASDAQ: ONCY (Oncolytics Biotech Inc.)

最近更新时间: 25 Jun, 1:20AM

0.674

0.04 (5.79%)

前收盘价格 0.637
收盘价格 0.620
成交量 514,963
平均成交量 (3个月) 714,758
市值 60,158,380
股市价格/股市净资产 (P/B) 23.83
52周波幅
0.330 (-51%) — 1.53 (127%)
利润日期 30 Jul 2025 - 4 Aug 2025
稀释每股收益 (EPS TTM) -0.290
总债务/股东权益 (D/E MRQ) 15.40%
流动比率 (MRQ) 3.20
营业现金流 (OCF TTM) -26.00 M
杠杆自由现金流 (LFCF TTM) -15.09 M
资产报酬率 (ROA TTM) -76.34%
股东权益报酬率 (ROE TTM) -213.85%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看跌
Biotechnology (全球的) 混合的 看跌
股票 Oncolytics Biotech Inc. 看涨 看涨

AIStockmoo 评分

0.4
分析师共识 3.5
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 0.0
技术振荡指标 0.0
平均 0.38

相关股票

股票 市值 DY P/E(TTM) P/B
ONCY 60 M - - 23.83
MRNA 9 B - - 1.05
HRMY 2 B - 11.90 2.83
MESO 2 B - - 4.47
ABCL 1 B - - 1.24
CVAC 1 B - 5.37 1.78

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 3.92%
机构持股比例 1.53%

所有权

姓名 日期 持有股份
Seeds Investor Llc 31 Dec 2024 189,941
Seacrest Wealth Management, Llc 31 Dec 2024 26,000
52周波幅
0.330 (-51%) — 1.53 (127%)
7.00 (938.73%)
总计 1 购买
公司 日期 目标价格 调整类型 价格@调整类型
Lake Street 13 Aug 2025 7.00 (938.73%) 购买 1.02

该时间范围内无数据。

日期 类型 细节
28 Aug 2025 公告 Oncolytics Biotech® Announces Upcoming Investor Conferences in September
14 Aug 2025 公告 Biotech Stocks Rally as Oncology Market Targets $866B by 2034
11 Aug 2025 公告 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
08 Aug 2025 公告 Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
08 Aug 2025 公告 Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
05 Aug 2025 公告 Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
29 Jul 2025 公告 Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
23 Jul 2025 公告 Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
22 Jul 2025 公告 Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
16 Jul 2025 公告 Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
10 Jul 2025 公告 Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
08 Jul 2025 公告 Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
30 Jun 2025 公告 Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
11 Jun 2025 公告 Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票